Skip to main content

Advertisement

Table 1 Samples cross-reacting to low-risk and unconfirmed genotypes

From: Cross-reactivity profiles of hybrid capture II, cobas, and APTIMA human papillomavirus assays: split-sample study

  Total (any of the three assays) HC2 cobas APTIMA
Overall  
  Positive test results, Total population (N = 5022) 1505 1024 (20.4 %) 1345 (26.8 %)a 838 (16.7 %)a
  Positive test results, Primary screening population age 30–65 years (N = 2859) 553 335 (11.7 %) 464 (16.2 %) 270 (9.4 %)
  Positive test results, Referral population (N = 887) 499 401 (45.2 %) 453 (51.1 %) 332 (37.4 %)
Cross-reactivity to low-risk genotypes  
 Total population (N = 5022)
  Cross-reacting samples 157 109 62 35
  Absolute cross-reactivity 109/5022 (2.2 %) 62/5022 (1.2 %) 35/5022 (0.7 %)
  Absolute cross-reactivity (vs. HC2) 1 (reference) 0.6 (0.4 to 0.8) 0.3 (0.2 to 0.5)
  Relative cross-reactivity 109/1024 (10.6 %) 62/1345 (4.6 %) 35/838 (4.2 %)
  Relative cross-reactivity (vs. HC2) 1 (reference) 0.4 (0.3 to 0.6) 0.4 (0.3 to 0.6)
 Primary screening population, age   30–65 years (N = 2859)
  Cross-reacting samples 61 43 20 13
  Absolute cross-reactivity 43/2859 (1.5 %) 20/2859 (0.7 %) 13/2859 (0.5 %)
  Absolute cross-reactivity (vs. HC2) 1 (reference) 0.5 (0.3 to 0.8) 0.3 (0.2 to 0.6)
  Relative cross-reactivity 43/335 (12.8 %) 20/464 (4.3 %) 13/270 (4.8 %)
  Relative cross-reactivity (vs. HC2) 1 (reference) 0.3 (0.2 to 0.6) 0.4 (0.2 to 0.7)
 Referral population (N = 887)
  Cross-reacting samples 58 47 16 8
  Absolute cross-reactivity 47/887 (5.3 %) 16/887 (1.8 %) 8/887 (0.9 %)
  Absolute cross-reactivity (vs. HC2) 1 (reference) 0.3 (0.2 to 0.6) 0.2 (0.1 to 0.4)
  Relative cross-reactivity 47/401 (11.7 %) 16/453 (3.5 %) 8/332 (2.4 %)
  Relative cross-reactivity (vs. HC2) 1 (reference) 0.3 (0.2 to 0.5) 0.21 (0.1 to 0.4)
 Primary screening vs. referral population
  Absolute cross-reactivity (95 % confidence interval) 0.3 (0.2 to 0.4) 0.4 (0.2 to 0.7) 0.5 (0.2 to 1.2)
  Relative cross-reactivity (95 % confidence interval) 1.1 (0.7 to 1.6) 1.2 (0.6 to 2.3) 2.0 (0.8 to 4.8)
Cross-reactivity to unconfirmed genotypes  
 Total population (N = 5022)
  Cross-reacting samples 223 49 162 56
  Absolute cross-reactivity 49/5022 (1.0 %) 162/5022 (3.2 %) 56/5022 (1.1 %)
  Absolute cross-reactivity (vs. HC2) 1 (reference) 3.3 (2.4 to 4.5) 1.1 (0.8 to 1.7)
  Relative cross-reactivity 49/1024 (4.8 %) 162/1345 (12.0 %) 56/838 (6.7 %)
  Relative cross-reactivity (vs. HC2) 1 (reference) 2.5 (1.8 to 3.4) 1.4 (1.0 to 2.0)
 Primary screening population, age 30–65 years (N = 2859)
  Total positive test results 553 335 (11.7 %) 464 (16.2 %) 270 (9.4 %)
  Cross-reacting samples 126 30 87 36
  Absolute cross-reactivity 30/2859 (1.0 %) 87/2859 (3.0 %) 36/2859 (1.3 %)
  Absolute cross-reactivity (vs. HC2) 1 (reference) 2.9 (1.9 to 4.4) 1.2 (0.7 to 1.9)
  Relative cross-reactivity 30/335 (9.0 %) 87/464 (18.8 %) 36/270 (13.3 %)
  Relative cross-reactivity (vs. HC2) 1 (reference) 2.1 (1.4 to 3.1) 1.5 (0.9 to 2.4)
 Referral population (N = 887)
  Total positive test results 499 401 (45.2 %) 453 (51.1 %) 332 (37.4 %)
  Cross-reacting samples 37 9 27 8
  Absolute cross-reactivity 9/887 (1.0 %) 27/887 (3.0 %) 8/887 (0.9 %)
  Absolute cross-reactivity (vs. HC2) 1 (reference) 3.0 (1.4 to 6.3) 0.9 (0.3 to 2.3)
  Relative cross-reactivity 9/401 (2.2 %) 27/453 (6.0 %) 8/332 (2.4 %)
  Relative cross–reactivity (vs. HC2) 1 (reference) 2.3 (1.3 to 5.6) 1.1 (0.4 to 2.8)
 Primary screening vs. referral population
  Absolute cross-reactivity (95 % confidence interval) 1.0 (0.5 to 2.2) 1.0 (0.7 to 1.5) 1.4 (0.7 to 3.0)
  Relative cross-reactivity (95 % confidence interval) 4.0 (1.9 to 8.3) 3.1 (2.1 to 4.7) 5.5 (2.6 to 11.7)
  1. aGenotype 66 was the only detected genotype among those that are targeted by cobas or APTIMA in 31 (2.3 %) and 11 (1.3 %), respectively, of the samples with positive test results